Sorafenib Tosylate: Uses, Dosage, Side Effects & Brands | MedexInfo

Sorafenib Tosylate

Rx

Generic NameSorafenib Tosylate

Therapeutic ClassMultikinase inhibitor, Antineoplastic agent

Common Strength200 mg tablet

PregnancyContraindicated

Indications ▼

Advanced hepatocellular carcinoma (HCC) in patients not eligible for surgery or transplant

Advanced renal cell carcinoma (RCC) in adults

Differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment

Mechanism & Pharmacokinetics ▼

Mechanism: Sorafenib is an oral multikinase inhibitor targeting Raf kinases and receptor tyrosine kinases (VEGFR, PDGFR). It inhibits tumor cell proliferation and angiogenesis.

Pharmacokinetics: Oral absorption; peak plasma concentration in 3 hours. Metabolized by CYP3A4 and UGT1A9. Half-life ~25–48 hours; primarily excreted via feces.

Dosage & Administration ▼

Dosage must be individualized based on patient condition, hepatic function, and tolerance. Always follow physician guidance.

Indication	Dose	Frequency / Notes
Advanced HCC / RCC / DTC	400 mg orally twice daily (200 mg tablets)	Continue until disease progression or unacceptable toxicity

Note: Dose reductions may be required for adverse effects such as hand-foot skin reaction, diarrhea, or hypertension.

Side Effects ▼

Hand-foot skin reaction (palmar-plantar erythrodysesthesia)

Diarrhea, nausea, vomiting

Hypertension

Fatigue, rash

Rare: cardiac ischemia, hemorrhage

Contraindications ▼

Hypersensitivity to sorafenib or any excipient

Pregnancy (Category X)

Severe hepatic impairment (Child-Pugh C)

Drug Interaction ▼

CYP3A4 inducers (rifampin, phenytoin): may reduce plasma levels

CYP3A4 inhibitors (ketoconazole, clarithromycin): may increase toxicity

Warfarin: monitor INR for bleeding risk

Pregnancy & Lactation ▼

Contraindicated in pregnancy; women of childbearing potential must use effective contraception

Breastfeeding not recommended

Clinical / Research Summary ▼

Clinical Role: First-line systemic therapy for advanced HCC, RCC, and refractory DTC in adults.

Advantage: Oral therapy with multikinase inhibition; anti-angiogenic and anti-proliferative effects.

Limitation: Adverse effects common; dose adjustments often required.

Monitoring: Liver function tests, blood pressure, skin reactions, cardiac status, and electrolytes.

Patient Counseling Points ▼

Take exactly as prescribed, preferably on an empty stomach

Report hand-foot skin reactions, diarrhea, or severe hypertension immediately

Regular blood tests and blood pressure monitoring required

Avoid pregnancy during treatment and for at least 2 weeks after

Storage & Handling ▼

Store below 30°C

Protect from moisture and light

Keep out of reach of children

Brand Names (Bangladesh & Global) ▼

Bangladesh:

Fenitab 200 mg Hepanib 200 mg Nexanib 200 mg Nobokin 200 mg Sofen 200 mg Sofenib 200 mg Sonib 200 mg Soracent 200 mg Sorafen 200 mg Soranix 200 mg Sorasiba 200 mg

Global:

Nexavar®

Medical Disclaimer: For educational purposes only. Not a substitute for professional medical advice.

Reference Hubs:

• Drug Class: Multikinase Inhibitors • Condition: Hepatocellular Carcinoma (HCC) • Condition: Renal Cell Carcinoma (RCC) • Condition: Thyroid Carcinoma (DTC)